Final answer:
The EMPEROR-Preserved trial studied the safety and effectiveness of JARDIANCE in patients with chronic heart failure. The specific LVEF range for the study is not provided in the information, but JARDIANCE is known for treating cardiovascular symptoms and managing heart failure when other medications are inadequate.
Step-by-step explanation:
The EMPEROR-Preserved trial was a study to evaluate the efficacy and safety of JARDIANCE in patients with chronic heart failure (NYHA Class II-IV) with left ventricular ejection fraction (LVEF). However, to provide a direct answer, the specific range of LVEF for inclusion in the EMPEROR-Preserved trial is not mentioned in the given information. The main purpose of JARDIANCE, in addition to standard of care therapy, is to treat and improve symptoms of cardiovascular conditions, including high blood pressure and heart failure. It is particularly effective when patients do not respond well to ACE inhibitors and diuretics and can also slow down certain types of irregular heartbeats, such as atrial fibrillation.
According to the EMA Note for Guidance on Non-clinical safety studies, any pharmaceutical intended for human clinical trials and marketing authorization must undergo a strict safety evaluation, which would apply to JARDIANCE as a treatment for heart failure.